Most cited papers from Eli Lilly (Switzerland)

Eli Lilly (Switzerland)

What are the most cited papers from Eli Lilly (Switzerland)?

The most cited paper from Eli Lilly (Switzerland) is "European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER Registry" (Dariusz Dudek, Zbigniew Siudak, Magnus Janzon et al., 2008), with 70 citations. Next come "Early versus periprocedural administration of abciximab for primary angioplasty: A pooled analysis of 6 studies" (58) and "A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study" (48).

Published TypeFieldAccess

Showing 45 of 45 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER Registry Dariusz Dudek, Zbigniew Siudak, Magnus Janzon et al. · American Heart Journal	20 Oct 2008	70
2	Early versus periprocedural administration of abciximab for primary angioplasty: A pooled analysis of 6 studies Jochen Gödicke, Marcus D Flather, Marko Noč et al. · American Heart Journal	Nov 2005	58
3	A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study Andrew McGovern, William Hinton, Silvio Calderara et al. · Diabetes Therapy Open access	4 Jan 2018	48
4	Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions Mathieu Uzzan, Yoram Bouhnik, María T. Abreu et al. · Journal of Crohn s and Colitis	2 Feb 2023	38
5	The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study James Benjamin Galloway, Jean-Philippe Capron, Francesco De Leonardis et al. · Rheumatology Advances in Practice Open access	2020	36
6	Framework for industry engagement and quality principles for industry-provided medical education in Europe Tamara L. Allen, Nina Donde, Eva Hofstädter-Thalmann et al. · Journal of European CME Open access	2017	26
7	Single‐Dose Pharmacokinetics, Safety, and Tolerance of Linopirdine (DuP 996) in Healthy Young Adults and Elderly Volunteers Henry J. Pieniaszek, William D. Fiske, Timothy D. Saxton et al. · The Journal of Clinical Pharmacology	1995	26
8	Data, not only in aerobiology: how normal is the normal distribution? E. Limpert, James Burke, Carmen Galán et al. · Aerobiologia	21 Jun 2008	24
9	Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer Miguel Martín, José Á. García-Sáenz, Luís Manso et al. · Future Oncology Open access	12 Aug 2020	19
10	Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries Alison M. Davie, Gebra Cuyún Carter, Alex Rider et al. · BMC Cancer Open access	7 Sep 2020	14
11	Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations Céline E. Toutain, Patrick Brossard, Stephen B. King et al. · BMC Veterinary Research Open access	17 Aug 2018	12
12	Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs Céline E. Toutain, Mark C. Heit, Stephen B. King et al. · BMC Veterinary Research Open access	28 Nov 2017	11
13	POS0668 REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA) B. Gilbert, D. Courvoisier, Denis Mongin et al. · Annals of the Rheumatic Diseases Open access	25 May 2021	9
14	Online continuing medical education as a key link for successful noncommunicable disease self-management: the CASALUD™ Model Héctor Gallardo‐Rincón, Rodrigo Saucedo-Martínez, Ricardo Mújica‐Rosales et al. · Diabetes Metabolic Syndrome and Obesity Open access	Oct 2017	9
15	Experiences and preferences about information on treatment-related side effects among patients with early breast cancer Antonio Di Meglio, Giuseppe Catanuto, Marzia Zambon et al. · The Breast Open access	6 Feb 2025	8
16	Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA Benoît Thomas P. Gilbert, Denis Mongin, Romain Aymon et al. · BMJ Open Open access	Mar 2024	8
17	Insulin exposure mitigates the increase of arterial stiffness in patients with type 2 diabetes and albuminuria: an exploratory analysis Daniel Gordin, Markku Saraheimo, Jaana Tuomikangas et al. · Acta Diabetologica Open access	22 May 2019	8
18	Susceptibility and Resistance of Pseudomonas aeruginosa to Antimicrobial Agents F. Bellido, Robert E. W. Hancock · Infectious agents and pathogenesis Book chapter	1993	8
19	Burden of Bowel Urgency in Patients With Ulcerative Colitis and Crohn’s Disease: A Real-World Global Study Raja Narayana Atreya, Isabel Redondo, Petra Streit et al. · Crohn s & Colitis 360 Open access	Jul 2024	7
20	Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study Alison M. Davie, G. Cuyun Carter, Alex Rider et al. · ESMO Open Open access	Aug 2021	7
21	The role of the pharmaceutical industry in promoting patient education Wolfgang Gruber, Julie Llewelyn, Christiane Arras et al. · Patient Education and Counseling	Sep 1995	7
22	A Comparison Between Simplified and Intensive Dose-Titration Algorithms Using AIR Inhaled Insulin for Insulin-Naive Patients with Type 2 Diabetes in a Randomized Noninferiority Trial Chantal Mathieu, Robert M Cuddihy, Richard F. Arakaki et al. · Diabetes Technology & Therapeutics	Sep 2009	7
23	A Policy Analysis on the Proactive Prevention of Chronic Disease: Learnings from the Initial Implementation of Integrated Measurement for Early Detection (MIDO) ROBERTO C. TAPIA-CONYER, Rodrigo Saucedo-Martínez, Ricardo Mújica‐Rosales et al. · International Journal of Health Policy and Management Open access	20 Feb 2017	6
24	Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study Axel U Dignass, Isabel Redondo, Petra Streit et al. · Current Medical Research and Opinion Open access	6 Nov 2023	3
25	Line probe and automated real-time PCR TB assays warrant adherence to strict quality assurance measures [Correspondence] Ákos Somoskövi, Linda M. Parsons, Cristina Gutiérrez et al. · The International Journal of Tuberculosis and Lung Disease	9 Apr 2012	3
26	Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe Javier P. Gisbert, Petra Streit, Isabel Redondo et al. · Current Medical Research and Opinion Open access	7 Aug 2023	2
27	Ten Years of Vildagliptin Stefano Del Prato · touchREVIEWS in Endocrinology Open access	2017	2
28	273P Experiences and preferences about information on treatment (tx)-related side effects (SE) among patients (pts) with early breast cancer (EBC) A. Di Meglio, Giuseppe Catanuto, Massimo Zambon et al. · ESMO Open Open access	May 2024	1
29	P188 Baricitinib effectiveness after a previous inadequate response to an alternative JAK inhibitor: results from the Swiss rheumatoid arthritis register Benoît T. P Gilbert, Delphine Sophie Courvoisier, Denis Mongin et al. · Lara D. Veeken Open access	23 Apr 2022	1
30	Comparative Evaluation of a New Autonomous AI Agent Versus Frontier LLMs for AI-Generated Patient Information Sheets on Pediatric Pathologies Zaid H. Khoury, Rata Rokhshad, Mohamed S. Sultan et al. · Cancers Open access	20 Sep 2026	0
31	Prevalence and clinical characterization of overweight and obesity in psoriatic arthritis: Data from a swiss registry Arnaud Monnard, Tatjana Rößler, Michael J. Nissen et al. · German Medical Science (German Research Foundation) Conference paperOpen access	9 Sep 2026	0
32	Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer Jose Sandoval, Patrick Neven, Anna Emde et al. · The Oncologist Open access	8 Jun 2026	0
33	Interchangeability of CSF and PET to identify Alzheimer's disease pathology Samantha C. Burnham, Anupa Arora, Leonardo Iaccarino et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring Open access	Apr 2026	0
34	Perspectives: governing the rise of decentralized science and artificial intelligence in healthcare Maryam Jessri, Tiffany Tavares, Andrew Hemingway et al. · Science and Public Policy	27 Nov 2025	0
35	Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data Phillen Nozibuyiso Maqhuzu, Derya Bocuk, Sebastian Boelz et al. · Annals of Hematology Open access	29 Sep 2025	0
36	Diagnostic journey of MCI/AD dementia patients, and importance of biomarkers testing: a real-world survey Z Vasileva-Metodiev Simona, Quevenco Frances-Catherine, Sanchez-Juan Pascual et al. Conference paper	Nov 2024	0
37	Establishing the interchangeability between CSF and PET to identify patients with Alzheimer’s disease pathology Quevenco Frances-Catherine, Boucher R.C., A. K. et al. Conference paper	Nov 2024	0
38	284TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer N. Matsubara, N. Agarwal, Mitchell Reed Smith et al. · Annals of Oncology Open access	Nov 2023	0
39	248 Sustained improvements in disease activity for up to two-years with ixekizumab in patients with active psoriatic arthritis who were either biologic-naïve or with previous inadequate response to tumour necrosis factor inhibitor therapy Deepak Rohit Jadon, Mani Haschemi Nassab, Katrien Van Beneden et al. · Lara D. Veeken	Apr 2019	0
40	251 Rapid and sustained improvements in patient-reported outcomes with ixekizumab in biologic-naïve and TNF-inadequate responder patients with psoriatic arthritis Hasan Tahir, Mani Haschemi Nassab, Andrew R. Bradley et al. · Lara D. Veeken	Apr 2019	0
41	AB0258 Impact of controlling disease activity on regaining normal physical function, and achieving no or limited pain in patients with rheumatoid arthritis treated with baricitinib Kurt de Vlam, Bruno Fautrel, M. van de Laar et al. · Annals of the Rheumatic Diseases Open access	Jun 2018	0
42	233 Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib Josef S Smolen, Maxime Dougados, Tsutomu Takeuchi et al. · Lara D. Veeken	Apr 2018	0
43	226 Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate-inadequate responder patient population Maxime Dougados, Bruno Fautrel, Mart A F J van de Laar et al. · Lara D. Veeken	Apr 2018	0
44	7th Middle East Regulatory Conference (MERC) Elaine Whiting, Afschin Khodaverdi-Afaghi, Fraser Stodart et al. · Drug Information Journal	May 2007	0
45	6th Middle East Regulatory Conference (MERC): Key Proceedings Brian Hewitt, Afschin Khodaverdi-Afaghi, Elaine Whiting et al. · Drug Information Journal	Apr 2005	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.